Skip to Main content Skip to Navigation
Journal articles

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors

Abstract : The identification of unique cell-surface proteins expressed on tumor cells, yet not expressed on normal tissues, has been challenging for pediatric malignancies. The cell sur-face tyrosine kinase ALK (CD246, anaplastic lymphoma kinase) is a promising target for neuroblastoma in that it is expressed in either native, mutated, or over-expressed forms on the plasma membrane surface
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00881036
Contributor : Ed. Bmc <>
Submitted on : Thursday, November 7, 2013 - 1:14:47 PM
Last modification on : Wednesday, October 14, 2020 - 4:14:18 AM
Long-term archiving on: : Saturday, February 8, 2014 - 7:15:08 AM

Files

Identifiers

Citation

Rimas Orentas, Paola Lopomo, William Babbitt, Marc Vigny, Crystal Mackall. ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors. Journal for Immunotherapy of Cancer, BMJ Publishing Group 2013, 1 (Suppl 1), pp.P27. ⟨10.1186/2051-1426-1-S1-P27⟩. ⟨inserm-00881036⟩

Share

Metrics

Record views

374

Files downloads

353